West Pharmaceutical Services Inc. Stock Rises Monday, Still Underperforms Market

Dow Jones12-17

DJ West Pharmaceutical Services Inc. Stock Rises Monday, Still Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of West Pharmaceutical Services Inc. (WST) inched 0.16% higher to $330.57 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.38% to 6,074.08 and the Dow Jones Industrial Average falling 0.25% to 43,717.48.

West Pharmaceutical Services Inc. closed $83.13 short of its 52-week high ($413.70), which the company achieved on February 7th.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Abbott Laboratories $(ABT)$ fell 0.67% to $112.62, Becton Dickinson & Co. $(BDX)$ rose 0.89% to $227.56, and Baxter International Inc. $(BAX)$ fell 2.97% to $29.42.

Trading volume (514,986) remained 133,513 below its 50-day average volume of 648,499.

Data source: Dow Jones Market Data, FactSet. Data compiled December 16, 2024.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

December 16, 2024 17:06 ET (22:06 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment